Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model

European Journal of Pharmacology

Volumn 818, Issue , 2018, Pages 449-456

  Briand, François ^a   Brousseau, Emmanuel ^a   Quinsat, Marjolaine ^a   Burcelin, Rémy ^b   Sulpice, Thierry ^a  

^a Physiogenex SAS   (France)

^b CHU RANGUEIL   (France)

Author keywords

Cholesterol; Hamster; Lipoprotein; Nonalcoholic steatohepatitis; Obeticholic acid

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN 1ALPHA1; COLLAGEN TYPE 1; CYTOCHROME P450 8B1; CYTOCHROME P450 FAMILY 8; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; OBETICHOLIC ACID; SCAVENGER RECEPTOR BI; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD36 ANTIGEN; CHENODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DYSLIPIDEMIA; GENE EXPRESSION; HAMSTER MODEL; INSULIN RESISTANCE; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; COMPLICATION; DIET; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; HAMSTER; LIVER; METABOLISM; PATHOLOGY; RAT;

ANIMALS; BODY WEIGHT; CD36 ANTIGENS; CHENODEOXYCHOLIC ACID; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CRICETINAE; DIET; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RECEPTORS, LDL;

EID: 85034763198     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.11.021     Document Type: Article

References (32)

1. Austin, G.E., Maznicki, E., Sgoutas, D., Comparison of phosphotungstate and dextran sulfate-Mg2+ precipitation procedures for determination of high density lipoprotein cholesterol. Clin. Biochem. 17 (1984), 166–169.
2. Basciano, H., Miller, A.E., Naples, M., Baker, C., Kohen, R., Xu, E., Su, Q., Allister, E.M., Wheeler, M.B., Adeli, K., Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E462–E473.
3. Briand, F., The use of dyslipidemic hamsters to evaluate drug-induced alterations in reverse cholesterol transport. Curr. Opin. Investig. Drugs 11 (2010), 289–297.
4. Briand, F., Thiéblemont, Q., Muzotte, E., Sulpice, T., High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters. J. Nutr. 142 (2012), 704–709.
5. Chen, W., Fan, S., Xie, X., Xue, N., Jin, X., Wang, L., Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. PLoS One, 9, 2014, e96056.
6. Cipriani, S., Mencarelli, A., Palladino, G., Fiorucci, S., FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51 (2010), 771–784.
7. Dong, B., Young, M., Liu, X., Singh, A.B., Liu, J., Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters. J. Lipid Res. 58 (2017), 350–363.
8. Farrell, G.C., Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J. Gastroenterol. Hepatol. 18 (2003), 124–138.
9. Hardy, T., Anstee, Q.M., Day, C.P., Nonalcoholic fatty liver disease: new treatments. Curr. Opin. Gastroenterol. 31 (2015), 175–183.
10. Hoekstra, M., SR-BI as target in atherosclerosis and cardiovascular disease – a comprehensive appraisal of the cellular functions of SR-BI in physiology and disease. Atherosclerosis 258 (2017), 153–161.
11. Ibrahim, S.H., Hirsova, P., Malhi, H., Gores, G.J., Animal models of nonalcoholic steatohepatitis: eat, delete, and Inflame. Dig. Dis. Sci. 61 (2016), 1325–1336.
12. Ikenaga, N., Peng, Z.W., Vaid, K.A., Liu, S.B., Yoshida, S., Sverdlov, D.Y., Mikels-Vigdal, A., Smith, V., Schuppan, D., Popov, Y.V., Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 66 (2017), 1697–1708.
13. Imajo, K., Yoneda, M., Kessoku, T., Ogawa, Y., Maeda, S., Sumida, Y., Hyogo, H., Eguchi, Y., Wada, K., Nakajima, A., Rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Int. J. Mol. Sci. 14 (2013), 21833–21857.
14. Kawasaki, T., Igarashi, K., Koeda, T., Sugimoto, K., Nakagawa, K., Hayashi, S., Yamaji, R., Inui, H., Fukusato, T., Yamanouchi, T., Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J. Nutr. 139 (2009), 2067–2071.
15. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J., Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
16. la Fleur, S.E., Luijendijk, M.C., van der Zwaal, E.M., Brans, M.A., Adan, R.A., The snacking rat as model of human obesity: effects of a free-choice high-fat high-sugar diet on meal patterns. Int J. Obes. 38 (2014), 643–649.
17. Lai, Y.S., Yang, T.C., Chang, P.Y., Chang, S.F., Ho, S.L., Chen, H.L., Lu, S.C., Electronegative LDL is linked to high-fat, high-cholesterol diet-induced non-alcoholic steatohepatitis in hamsters. J. Nutr. Biochem. 30 (2016), 44–52.
18. Li, T., Chiang, J.Y., Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res., 2009, 2009, 501739.
19. Matsuzaki, Y., Bouscarel, B., Ikegami, T., Honda, A., Doy, M., Ceryak, S., Fukushima, S., Yoshida, S., Shoda, J., Tanaka, N., Selective inhibition of CYP27A1 and of chenodeoxycholic acid synthesis in cholestatic hamster liver. Biochim. Biophys. Acta 1588 (2002), 139–148.
20. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Kowdley, K.V., McCullough, A., Terrault, N., Clark, J.M., Tonascia, J., Brunt, E.M., Kleiner, D.E., Doo, E., NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
21. Pencek, R., Marmon, T., Roth, J.D., Liberman, A., Hooshmand-Rad, R., Young, M.A., Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes. Metab. 18 (2016), 936–940.
22. Sawangjit, R., Chongmelaxme, B., Phisalprapa, P., Saokaew, S., Thakkinstian, A., Kowdley, K.V., Chaiyakunapruk, N., Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine, 95, 2016, e4529.
23. Softic, S., Cohen, D.E., Kahn, C.R., Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig. Dis. Sci. 61 (2016), 1282–1293.
24. Srivastava, R.A., He, S., Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol. Cell Biochem. 345 (2010), 197–206.
25. Vos, M.B., Lavine, J.E., Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57 (2013), 2525–2531.
26. Wang, P.R., Guo, Q., Ippolito, M., Wu, M., Milot, D., Ventre, J., Doebber, T., Wright, S.D., Chao, Y.S., High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur. J. Pharmacol. 427 (2001), 285–293.
27. Walkin, L., Herrick, S.E., Summers, A., Brenchley, P.E., Hoff, C.M., Korstanje, R., Margetts, P.J., The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenes. Tissue Repair, 6, 2013, 18.
28. Weber, O., Bischoff, H., Schmeck, C., Böttcher, M.F., Cholesteryl ester transfer protein and its inhibition. Cell. Mol. Life Sci. 67 (2010), 3139–3149.
29. Wree, A., Broderick, L., Canbay, A., Hoffman, H.M., Feldstein, A.E., From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 627–636.
30. Xu, Y., Li, F., Zalzala, M., Xu, J., Gonzalez, F.J., Adorini, L., Lee, Y.K., Yin, L., Zhang, Y., Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice. Hepatology 64 (2016), 1072–1085.
31. Xu, J., Liu, X., Koyama, Y., Wang, P., Lan, T., Kim, I.G., Kim, I.H., Ma, H.Y., Kisseleva, T., The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front. Pharmacol., 22, 2014, 167.
32. Zhang, D.G., Zhang, C., Wang, J.X., Wang, B.W., Wang, H., Zhang, Z.H., Chen, Y.H., Lu, Y., Tao, L., Wang, J.Q., Chen, X., Xu, D.X., Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation. Toxicol. Appl. Pharmacol. 314 (2017), 39–47.